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Osteogenesis imperfecta is an inherited disorder of connective tissue characterized by 
bone fragility and low bone mass. It is caused by quantitatively or structurally abnormal 
type I collagen. Bisphosphonates, a group of anti-resorptive drugs, are commonly used as 
a medical therapy in children with osteogenesis imperfecta. A large number of studies 
have demonstrated their beneficial effects on bone mass and density. Much of their 
effects, especially long-term effects, in growing children remains unclear, however. This 
investigation studied the effects of bisphosphonate treatment on the development of 
cranial base pathology, dental development, and characteristics of femoral fractures. In 
addition, zoledronic acid, the most recent intravenous bisphosphonate, was evaluated in 
the treatment of children with osteogenesis imperfecta.  
 
The patient population comprised children with osteogenesis imperfecta followed at the 
Metabolic Bone Clinic, Children's Hospital, Helsinki University Hospital, Finland. The 
treatment response of zoledronic acid was analyzed in 17 children with mild osteogenesis 
imperfecta. The treatment effectively increased bone mass and density, and a decreasing 
trend in fracture incidence was found. These results were comparable to pamidronate, the 
most studied intravenous bisphosphonate in children with osteogenesis imperfecta. 
However, zoledronic acid has the advantage of more convenient infusion protocol. 
 
Cranial base pathology is one of the most severe complications of osteogenesis 
imperfecta. The longitudinal analysis of skull base morphology from lateral skull 
radiographs obtained in 22 children with osteogenesis imperfecta indicated that cranial 
base pathology may develop despite of bisphosphonate treatment. The analysis also 
suggested, however, that treatment started in infancy may delay the development of the 
pathology. Regarding the dental development, bisphosphonate treatment was found, in the 
evaluation of dental panoramic tomographs of 22 patients, to delay the development of the 
permanent dentition. However, since the children with osteogenesis imperfecta were found 
to be inherently advanced in terms of dental age and eruption of the permanent teeth, the 




Atypical femoral fractures caused by bisphosphonate treatment have recently been a major 
concern in women with postmenopausal osteoporosis. The radiographic analysis of 127 
femoral fractures occurred in 39 children with osteogenesis imperfecta showed that the 
fractures often represented atypical characteristics regardless of the patients’ previous 
exposure to bisphosphonates. Furthermore, no changes in the location or configuration of 
the fractures were found in relation to bisphosphonate treatment. Instead, the 
characteristics reflected the severity of osteogenesis imperfecta. 
 
In conclusion, bisphosphonate therapy can be considered as a reasonably effective and 
well tolerated treatment in children with osteogenesis imperfecta. Further studies are, 
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Osteogenesis imperfecta (OI) is an inherited disorder characterized by bone fragility, 
skeletal deformities, and substantial growth deficiency. The clinical severity varies widely, 
ranging from mild forms without fractures to intrauterine fractures and perinatal lethality. 
Many other organ systems can also be involved. Typical extraskeletal features are bluish 
discoloration of the sclerae and dentinal abnormality, often referred to as type 1 
dentinogenesis imperfecta. However, these extraskeletal features are also absent in many 
patients. (Rauch and Glorieux, 2004) The worldwide incidence of OI is approximately 
1/15,000 to 1/20,000 births (Forlino and Marini, 2016).  
 
OI is a disorder of quantitatively or structurally abnormal type I collagen, the most 
abundant protein in bone. In the great majority of the individuals with OI, the disease-
causing mutation resides in one of the two genes encoding type I collagen (COL1A1, 
COL1A2). Recently, mutations in several other genes have been identified to cause OI as 
well. These genes code for proteins responsible for post-translational modification, 
folding, or secretion of type I collagen. (Forlino and Marini, 2016) 
 
Before the time of medical therapies, the treatment of children with OI comprised of 
physical therapy, rehabilitation and surgical management. The goal was basically the same 
as today: taking care of muscle condition, maximizing functional capabilities, and 
preventing fractures. Surgical orthopedic interventions included correction osteotomies 
and use of intramedullary telescopic roding to correct long-bone deformities and prevent 
fractures. The immobilization after surgery or fracture was limited to the time strictly 
necessary for healing. These non-medical treatments still remain the mainstay of treatment 
in children with OI, albeit the introduction of bisphosphonates has had a revolutionizing 
impact on it. (Antoniazzi et al., 2000) 
 
Bisphosphonate (BP) therapy is today by far the most used medical treatment modality in 
children with OI. A large number of studies, mainly performed with intravenous 
pamidronate, have shown their beneficial impact on bone mass and mineral density 






improvement in clinical outcomes, such as fracture rate, mobility, and quality of life 
(Astrom and Soderhall, 2002; Lindahl et al., 2016). However, the question about clinical 
benefits still remains controversial.  
 
As anti-resorptive agents, BPs reduce the remodeling activity in bone. This has been 
speculated to cause accumulation of microcracks, potentially leading to stress fractures in 
long-term use. Bone resorption also plays an important role in many developmental 
processes in a growing child, such as development and eruption of the dentition, and some 
concerns remain whether BP treatment would have a detrimental effect on these processes. 
The present study was undertaken to evaluate the benefits and long-term safety of BP 







2 Review of the literature 
2.1 Bone 
2.1.1 Structure 
Bones can be divided in three categories according to the shape: long bones are located in 
the shafts of limbs; short bones are cuboidal in shape and located in wrists and ankles; flat 
bones, such as sternum, ileum, and skull, protect inner organs. Some bones, such as facial 
bones, do not fall within any of these categories and are often called irregular bones. 
Furthermore, macroscopically bone can be divided into compact (i.e. cortical) bone and 
trabecular (i.e. cancellous or spongy) bone. All bones have a superficial layer of compact 
bone that provides the strength for weight bearing. The more capacity for weight bearing 
is needed, the thicker this layer is. Hence, the layer of compact bone is thickest near the 
middle of the shafts (diaphysis) of lower-extremity long bones. Trabecular bone forms the 
central mass of all bones and is the metabolically active part of the skeleton. Bone marrow 
is located within the medullary cavity between the trabeculae of the trabecular bone. 
(Clarke, 2008) 
2.1.2 Bone cells 
Osteoblasts 
Osteoblasts are bone-forming cells which derive from mesenchymal progenitor cells, 
commonly referred to as mesenchymal stem cells. The active osteoblasts form initial 
unmineralized bone, called osteoid, by secreting type I collagen and other bone matrix 
proteins. Among these bone matrix proteins are alkaline phosphatase (ALP) and 
osteocalcin, used clinically as markers of osteoblast activity/bone-forming activity. 
Subsequently, the osteoblasts initialize and regulate mineralization of the osteoid by 
secreting vesicles that concentrate calcium and phosphate. At the completion of bone 
formation, approximately 50 to 70% of the osteoblasts undergo apoptosis, while the rest 










By constant secretion, osteoblasts surround themselves with osteoid and gradually isolate 
themselves from the adjacent cells. Of the osteoblasts embedded in the bone matrix, those 
that do not undergo apoptosis further differentiate to osteocytes, the main cells of already 
formed bone. (Dirckx et al., 2013) Although surrounded by osteoid, osteocytes connect to 
adjacent osteocytes by long cytoplasmic processes and form a network-like structure, 
serving as mechanotransduction network, by which they sense mechanical loading to 
optimize the relation of bone formation and resorption according to the need (Bonewald, 
2011). They are also responsible for maintaining the bone matrix, and are even capable of 
synthesizing new matrix (Zambonin Zallone et al., 1983). Osteocytes also have a limited 
capability to degrade the bone matrix, and this in its turn is thought to be related to 
calcium homeostasis (Wysolmerski, 2013). 
 
Osteoclasts 
Osteoclasts, the cells responsible for bone resorption, originate from bone marrow and are 
members of monocyte/macrophage family. Two cytokines crucial to osteoclastogenesis 
are receptor activator of nuclear factor kappa B ligand (RANKL) and macrophage-colony 
stimulating factor (M-CSF). Osteoprotegerin (OPG) in turn lowers bone resorption 
activity by inhibiting RANKL. (Clarke, 2008) Osteoclasts are multinucleated and 
polarized cells that have extensively folded surface (ruffled border) against the bone 
supposed to be resorbed. The cell membrane of the ruffled border contains a large number 
of proton pumps that form an acidic microenvironment (pH values of up to 3 or less). The 
acidified milieu dissolves the mineral component of bone, and organic matrix, mainly type 
I collagen, becomes exposed and subsequently degraded by cathepsin K and 
metalloproteinases. The organic and inorganic degradation products are then endocytosed 
from the ruffled border membrane and transcytosed through the osteoclast to the 








2.1.3 Bone matrix and type I collagen 
 
Majority of the bone mass consists of extracellular matrix, called bone matrix. It is mainly 
composed of minerals (50 to 70% of the weight), organic matrix (20 to 40%), water (5 to 
10%), and a small amount of lipids. The mineral portion is almost completely comprised 
of crystallized hydroxyapatite [Ca10(PO4)6(OH)2] that provides hardness property, 
important to withstand mechanical loads. In addition to hydroxyapatite, bone matrix also 
contains carbonate, magnesium and acid phosphate serving as a source for calcium, 
magnesium and phosphate homeostasis. (Boskey, 2013) 
 
The most abundant protein in bone matrix is type I collagen constituting approximately 
90% of the organic phase of bone matrix (Boskey, 2013). Type I procollagen is a large 
structural protein consisting of two α1(I) polypeptide and one α2(I) polypeptide chain, 
which fold to a triple-helical formation. The triple-helical structure is essential for its 
function and requires a glycine residue at every third position of the chains. The complex 
folding process is multistage and requires several chaperon proteins. After folding, the 
procollagen molecule is secreted out of the cell, and the propeptides at the N- and C-
termini (PINP and PICP) are cleaved off (Figure 1). Now, the protein is called type I 
collagen and it spontaneously polymerizes and forms fibrils. (Forlino and Marini, 2016) 
The functions of type I collagen include providing elasticity to bone, stabilizing bone 
matrix, supporting initial mineral deposition and binding other macromolecules. The 
noncollagenous protein content of bone matrix comprises a wide variety of proteins 
having a number of different functions. Among these functions are organization of bone 
matrix, coordination of cell-matrix and mineral-matrix interactions, metabolism, and 








Figure 1. Type I procollagen molecule. The N- and C-terminal ends are cleaved off 
extracellularly, and can be used as biomarkers for bone turnover (modified from Urena & 
De Vernejoul, 1999). 
2.1.4 Bone growth and turnover 
 
Bone can be formed two ways: The bones of the extremities and weight-bearing axial 
skeleton develop with cartilage precursor (endochondral ossification). Flat bones, such as 
most of the bones of the skull, are in turn formed directly in mesenchymal condensations 
without any cartilage precursors (intramembranous ossification). The latter process is 
similar to periosteal bone formation that also takes place on the endochondral bones. The 
bones of the cranial base are an exception to the other bone of the skull, and form through 
endochondral ossification. After ossification of the rest of the long bones in the early 
childhood, special regions of cartilage remain between epiphyseal and metaphyseal bone 
at the ends of the developing long bone. These regions, called epiphyseal growth plates, 
are responsible for longitudinal growth, and retain their ability to grow new bone until the 
adult height is reached. The proliferating cells in the growth plates are chondrocytes that 
exceptionally start to produce a large amount of type I collagen. The matrix then calcifies 
which leads to degeneration and apoptosis of the chondrocytes. At the metaphysis, the 






and osteoblasts replace it with new bone (primary trabecular bone). The new bone is 
further reorganized by osteoblasts and osteoclasts to respond the accommodation and 
physical requirements of the bone. All these events happen in their own differentiated 
zones, thus pushing epiphysis away from the diaphysis (Figure 2). (Berendsen and Olsen, 
2015; Rauch, 2005) 
 
Throughout the whole life, bone undergoes constant renewal and adaptation. This can 
occur in two ways: by modeling and by remodelling (Figure 2). Modeling is characteristic 
of growing bone, although it occurs to a lesser extent also in adults. In modelling, the bone 
adapts to mechanical forces by altering its mass, size, and shape. It is a process where 
bone forming osteoblasts and bone resorbing osteoclasts act on different surfaces of the 
bone and are not necessarily coupled. The net effect is often increase of cortical thickness 
and bone mass. The purpose of remodeling is not to alter bone features like with 
modeling, but rather to maintain bone strength and mineral homeostasis. The remodelling 
process resorbs old bone and forms new bone to replace it, hence preventing accumulation 
of micro fractures. The group of osteoclasts and osteoblasts acting together form a 
remodeling unit or basic multicellular unit. The cells of these units are in constant 
interaction, keeping the difference between removed and added bone (remodeling balance) 
close to zero in young adults. A decade or two after attainment of peak bone mass, the 
bone formation rate, however, fails to keep in pace with bone resorption, and bone loss 
begins. As opposed to modeling, remodeling occurs much more frequently in trabecular 
bone than in cortical bone; 80% of bone remodeling takes place in cancellous bone that 






Figure 2. Bone growth and turnover. The longitudinal growth of long bones takes place in 
epiphyseal growth plates, where different phases of bone growth take place in five distinct 
zones: zone of reserve, zone of proliferation, zone of maturation and hypertrophy, zone of 
calcification, and zone of ossification. The shape of the bone is then altered in a process 
called modelling. Remodeling is a process, where old bone is replaced by new one. 
2.1.5 Methods to assess bone and its metabolism 
Reflecting the wide variety of functions that bone has, multiple different methods have 
been created to assess it. Radiological methods are mostly used for assessing the mass and 
structure, whereas biological methods measure mostly mineral metabolism and activity of 
bone cells. Bone biopsies can give us a specific view of bone at a histological level. 
Because of their invasive nature, they are, however, mostly used only in scientific research 








Throughout the life, bone undergoes constant remodelling, to maintain structural quality. 
Specific molecules, bone markers, can be used to assess the intensity of this process. 
These markers can be measured in blood or urine. ALP and osteocalcin reflect the bone 
formation activity (Hlaing and Compston, 2014). PINP and PICP also are bone formation 
markers, but as cleavage products of type I procollagen, they also reflect the production of 
type I procollagen outside bone (Hlaing and Compston, 2014; Risteli and Risteli, 1993). 
Regarding bone resorption, the most used markers are the N-terminal and C-terminal type 
I collagen telopeptides (INTP and ICTP, respectively), which are small peripheral 
fragments of type I collagen degraded by osteoclasts (Figure 1).  ICTP can be measured in 
blood or urine, but INTP only in urine. When measured in urine, ICTP is called CTx, and 
INTP NTx. All these bone markers reflect the intensity of whole remodelling process and 
can’t be used to assess the remodeling balance (Szulc et al., 2000). In contrast to adults, in 
growing children, both skeletal growth and high bone turnover rate elevate the bone 
markers (Huang et al., 2011). Since the normative data is, however, currently limited, the 




The most used radiological method to evaluate the bone mineral density (BMD) is dual-
energy X-ray absorptiometry (DXA). In DXA, the bone mineral content (BMC) is 
assessed within a selected bone area of interest by detecting the attenuation of two photon 
beams with different energies. Areal bone mineral density (aBMD) is then calculated by 
dividing BMC by the area, reported in g/cm². Hence, DXA does not adequately take into 
account the architectural structure and shape of the bone, underestimating bone mineral 
density, especially in children with short stature (Gafni and Baron, 2004). However, 
because of its widespread availability, high reproducibility, low radiation exposure, and 
relative affordability, it has established its role as a method of choice in diagnostics of 
osteoporosis. In children, the BMD values are compared with comprehensive database of 
age- and sex-matched controls and the results are reported as S.D. scores (z-scores) 
(Gordon et al., 2008). The recommended sites for measurements are posterior-anterior 






reflects mostly cortical bone. In children, the hip is a less reliable site of measurement 
because of variability in positioning and difficulties in identifying bony landmarks 
(Golden and Abrams, 2014). Possible significant scoliosis and metal implants can impair 
the accuracy of measurements (Estrada et al., 2014).  
 
Another non-invasive method to assess bone density and fracture risk is peripheral 
quantitative computed tomography (pQCT), in which the measurement sites are distal 
tibia and/or distal radius (Binkley and Specker, 2000). As an advantage over DXA, it 
provides volumetric BMD, as well as information about bone geometry and strength. 
Currently, pQCT is, however, mainly used in research, while the use of different imaging 
protocols and the lack of reference values in children limit its use in clinical practice 
(Fonseca et al., 2013). Bone quantitative ultrasonography (QUS) is a safe, fast and easy to 
use method to evaluate bone tissue, and is free of ionizing radiation.  The most used sites 
for measurement are heel and phalanges. In addition to mineral density, it measures 
connectivity, elasticity and micro-architecture providing a measure of bone quality. 
However, due to a variability of devices and lack of standardization, the method QUS is 
not recommended in clinical practice for diagnosis of pediatric osteoporosis (Wang et al., 
2014; Pezzutti et al., 2017).  Despite the new methods in the evaluation of bone, 
conventional radiography has still maintained its role as gold standard. It is used to assess 
skeletal features of bone dysplasias as well as focal abnormalities. Furthermore, almost all 
fractures are detected and followed up with conventional radiographs, magnetic resonance 
imaging and computed tomography, primarily serving as secondary methods to assess 
occult and complex fractures. Conventional radiography also plays an important role in 
the evaluation of vertebral fractures, where the diagnostic accuracy of current DXA 
images is found to be insufficient (Mayranpaa et al., 2007). 
2.2 Teeth and development of dentition 
Teeth, after completed formation are considerably stable organs with scarce regeneration 
mechanisms. Their most abundant structural tissue is dentin, being covered by enamel in 
the crown and by cementum in the root. Dentin is bone-like tissue, produced by 






like cells exist in dentin. Instead, a single layer of odontoblasts remains lying on the 
surface of the dental pulp with long cell processes embedded in the dentinal tubules, and 
are responsible for the maintenance of dentin. However, their regeneration capability is 
limited and no remodeling occurs in dentin. (Bleicher, 2014) Cementum, a thin layer 
covering the roots of the teeth, also is bone-like tissue that is produced by osteoblast-like 
cementoblasts and maintained by osteocyte-like cementocytes. It is, however, structurally 
soft, and its main function is to serve, together with the principal fibers of periodontal 
ligament, as a connective layer between the dentin and the surrounding alveolar bone. 
(Yamamoto et al., 2010) Enamel, though being the hardest tissue in the human body and 
consisting from 96% of hydroxyapatite crystals, is not connective tissue. It is instead 
mineralized material derived from ameloblasts, epithelial cells that degenerate at the time 
of tooth eruption. Hence, matured enamel is incapable of becoming regenerated. (Varga et 
al., 2015) 
 
Humans have two separate dentitions. The primary dentition, deciduous teeth, comprises 
20 teeth and emerges usually between the first 6 months and 3 years of life. Typically, 
between the ages of 6 and 13 years, the deciduous teeth are lost, and 32 larger and more 
durable permanent teeth emerge, these are called the permanent dentition (Sperber et al., 
2001) (Table 1). The development of teeth starts during the fetal period when the oral 
epithelium and the underlying neural-crest-derived mesenchyme form the tooth bud. After 
the complex course of histological and morphological differentiation, the tooth bud 
develops into so-called bell stage. During this process, enamel knot, located at the tip of 
the epithelial bud, serves as a signaling center regulating the morphogenesis of the 
developing tooth (Thesleff et al., 2001). In the bell stage, the mesenchymal cells are 
developed into dentin-secreting odontoblasts and the surrounding epithelium into enamel-
secreting ameloblasts in the area preceding crown. (Caton and Tucker, 2009) The 
mesenchyme surrounding the tooth forms dental follicle, a loose connective tissue sac that 
gives rise to cementoblasts and periodontal ligament (Honda et al., 2010). The 
calcification of the deciduous tooth germs commences already prenatally and is completed 
shortly after it. (Kjaer, 2014) Permanent teeth develop in a same manner, but budding 
from the invaginating dental epithelium of the primary teeth. The mineralization of the 






permanent teeth normally erupt when their root length has reached three quarters of the 
expected length. First permanent molars and maxillary central incisors make an exception, 
often erupting with half-way developed roots. Another exception is made by the maxillary 
canines that do not erupt until their roots have obtained full length (Haavikko, 1970). The 
typical ages for the eruption of permanent teeth are shown in Table 1. 
 
The mechanisms of tooth eruption still remain largely unclear. The crucial role of 
osteoblasts and osteoclasts in the eruption pathway is, however, evident. Osteoblasts form 
new alveolar bone at the base of the tooth, whereas osteoclasts resorb bone apical to the 
tooth, thus producing together an intra-osseous movement force towards the oral cavity 
(Wise et al., 2011). The dental follicle also has a decisive role in this process, inducing 
and regulating the cells (Marks and Cahill, 1984). The induction of the whole event seems 
to be genetically programmed and not affected by external factors. In fact, the reference 
values of the eruption schedule dating back to 1933 by Logan and Kronfeld (Logan and 
Kronfeld, 1933) is still accurate, while growth curves and timing of the puberty have 
shifted drastically. The mechanisms of eruption do not differ between deciduous and 
permanent teeth except that with permanent teeth the overlaying root of the deciduous 
tooth has to be resorbed. 
  






















































































































































































































































































































































































































































































































































































































































2.3 Osteogenesis imperfecta 
Osteogenenesis imperfecta (OI), also known as brittle bone disease, is an inherited 
disorder characterized by bone fragility and an insufficient amount of bone, causing 
increased fracture incidence and bone deformities. The earliest mention of OI-like patients 
in the literature date back to 1788 when Swede Olof Jakob Ekman described in his thesis a 
condition resembling OI in a family where three generations were affected (Ekman 1788). 
He named the condition “osteomalacia congenita”. The current term “osteogenesis 
imperfecta” has been used in the medical literature since 1840s (Baljet 2002). 
2.3.1 Genetics and pathophysiology 
Approximately 90% of the OI patients have so-called classical form of disorder that is 
dominantly inherited. The classical form is caused by a mutation in one of the two genes, 
COL1A1 and COL1A2, encoding either of the two α-chains of type I collagen, the main 
organic component of the bone and dentin. Over 1,500 different mutations have been 
reported (Forlino et al., 2011). The mild cases are usually caused by premature 
termination codons, leading to degradation of the protein in a process called nonsense-
mediated decay. However, since the other allele is intact, osteoblasts still secrete intact 
type I collagen, the amount of which is just reduced to approximately half. (Willing et al., 
1996) In more severe cases, the mutation usually causes substitution of one of the glycine 
recidues (80%), or splicing defect resulting in an in-frame deletion of a section of the 
chain (20%). The glycine residue is repeated as every third amino acid almost throughout 
the α-chain, which is essential for the formation of the triple-helical structure of collagen. 
These mutations ultimately lead to structurally abnormal and thus functionally impaired 
protein, albeit of normal quantity. (Forlino et al., 2011) 
 
In 2-5 % of the OI patients, the disorder is inherited recessively. In the last 15 years, an 
increasing number of mutations in different protein-coding genes have been reported to 
cause OI (Table 2). These mutations usually affect proteins that participate in post-






action is best described for the proteins coded by CRTAP, LEPRE1, PPIB, SERPINH1, 
and FKBP10.  Cartilage-associated protein (CRTAP), prolyl 3-hydroxylase 1 (P3H1), and 
cyclophilin B (CyPB) form together the collagen prolyl 3-hydroxylation complex that 
modifies collagen in the endoplasmic reticulum; the collagen prolyl 3-hydroxylation 
complex is required for its proper folding. Heat shock protein 47 (HSP47) and FK506 
binding protein 65 (FKBP65) assist in turn in the formation and secretion of the 
procollagen triple helix. Impaired function of these proteins leads to recessively inherited 
OI with a moderate to severe phenotype. (Forlino et al., 2011; Forlino and Marini, 2016) 
A mutation in the gene IFITM5 that codes for interferon-induced transmembrane protein 5 
has, on the other hand, been identified as a causative factor behind dominantly inherited 
OI and accounting for approximately 5% of OI cases. The mutation causes moderately 
severe OI with unique clinical features (Cho et al., 2012; Semler et al., 2012), described 
later in the section defining the classification of OI. 
 
Since the genetic defects causing OI affect type I collagen protein, the main organic 
component of bone, it is not surprising that the bone material quality of patients with OI is 
decreased. Proper hydroxyapatite crystallization requires attachment to type I collagen 
protein. In OI, the hydroxyapatite crystals are smaller but more abundant than normally 
that leads to hypermineralization of the bone (Traub et al., 1994). The abnormally high 
matrix mineralization in conjunction with disorganization of the crystals is suggested to be 
a major contributor to the stiffness and hardness of bone in OI (Fratzl et al., 1996). In 
addition to the impaired bone material quality, another considerable contributor to bone 
fragility in OI is low bone mass. Histomorphometric studies of iliac crest biopsies of 
patients with OI have shown markedly lower cortical width and diminished external bone 
size, suggesting a defect in cortical bone modeling (Ste-Marie et al., 1984; Rauch et al., 
2000). Moreover, OI is also characterized by a low amount of cancellous bone as a result 
of low trabecular number and thickness. The bone remodeling is found to be accelerated. 
The increase in number of osteoblasts outweighs their functional defect, thus leading to 
increased bone formation. Since the osteoclast activity is, however, increased as well, no 
net gain in bone mass occurs. (Rauch et al., 2000) 















































































































































































































































































































































































































































































































































































































































































2.3.3 Clinical features and non-medical treatment 
The incidence of OI is about 1/15,000-20,000 births worldwide (Forlino and Marini, 
2016). Kuurila and colleagues suggested six per 100,000 individuals to be affected with 
disorder in Finland (Kuurila et al., 2002).  
 
The main feature of OI is bone fragility that causes increased fracture incidence 
throughout the life, and in severe cases, even prenatally. The fracture incidence markedly 
varies according to the severity of disease, patients representing the mildest end of the 
spectrum having not even a single fracture during their life, and patients representing the 
severest end suffering multiple major fractures annually (Rauch and Glorieux, 2004). The 
fracture incidence also varies by age. It commonly drops substantially after growth spurt, 
and rises again in women after the menopause in the adulthood when bone mass 
hormonally begins to decrease (Paterson CR et al., 1984). The fractures can occur due to 
very minor traumas, for example with infants by normal handling. The care givers often 
undergo significant distress and sometimes the situation can even lead to over-caution and 
interfere with proper muscular development. Hence, valid information for the family lies 
at the core of the overall management of a newborn child with OI (Bozkurt et al., 2014). 
In patients with severe OI, frequent long-bone fractures together with impaired bone mass 
leads to bending of the long bones. These deformities often lead to physical limitations, 
and the patients commonly need to use mobility aids, such as wheel chair and wheeled 
walker. Physiotherapy and rehabilitation hold true as a mainstay of treatment of children 
with OI improving markedly mobility and well-being (Binder H et al., 1993). Correction 
osteotomies and intramedullary roding is used to straighten the bended femora and tibiae, 
typically, and to maintain the mobility. Scoliosis and kyphosis of the thoracolumbar spine, 
due to multiple vertebral compression fractures, are also common in OI. A thoracolumbar 
kyphoscoliosis, in conjunction with rib fractures and muscle weakness, may even progress 
to a level that leads to respiratory insufficiency and cor pulmonale, which have been the 







The most prevalent secondary feature of OI is short stature, though the magnitude varies 
markedly according to the severity of the disease. Most of the patients with mild or 
moderate OI have normal birth length, but those with severe OI, exhibit retarded growth 
already prenatally. The growth rate of patients with moderate to severe OI is greatly 
reduced, adult patients with moderate OI standing in a height of early teenager, and with 
severe OI, in a height of prepubertal child. Patients with mild OI grow parallel to normal 
grow curve and have normal adult height or slightly shorter. (Vetter et al., 1992) The 
reason for shorter stature is unclear. Vertebral compression fractures, scoliosis, and long 
bone bending contribute to short standing height but they do not explain the deficient 
growth. It has been speculated weather deviations in growth hormone axis would play a 
part, since children with OI  have been found to be unresponsive to stimulation with 
insulin-like growth factor I (Marini et al., 1993), and about half of the patients with 
moderate OI had beneficial effects  in a study with growth hormone therapy (Marini et al., 
2003). 
 
In addition to bone, OI also affects other types of connective tissue. The laxity of 
ligaments lies behind the hypermobility of joints, which is a common symptom. It can 
lead to manifold orthopedic problems, pes planovalgus being particularly frequent 
(Mirzayan et al., 2000). Other extraskeletal features characteristic of OI include skin 
hyperlaxity, bruising and bleeding tendency. The overlap in the features of Ehlers-Danlos 
syndromes is evident. Patients with OI have an increased risk of valvular heart diseases, 
most frequently involving the aortic and mitral valves, and increased aortic diameter 
(Ashournia et al., 2015). However, cardiovascular involvement is relatively rare in OI, 
with the prevalence of aortic valve regurgitation, the most common valvular abnormality, 
being 1.8%. It does not correlate with the severity of OI, either (Hortop et al., 1986). 
 
One distinctive feature of OI is bluish hue of the sclerae. Most of the people with OI have 
blue sclerae, but some will have white sclerae. The bluish hue may be a result from 
decreased scleral thickness, but it can also occur with normal thickness. In the latter case, 
it has been suggested to be a result of a different proteoglycan compositions, and 
therefore, different hydrations, reflecting wavelengths of blue color (Marini and Smith, 






that develop from accessory ossification centers within the cranium (Bellary et al., 2013). 
They are frequently found in infants with moderate to severe OI. Both features have little 
clinical significance but they serve as diagnostic signs supporting the diagnosis of OI. 
 
One of the most serious complications of OI, and occurring predominantly in patients with 
the more severe subtypes, are cranial base anomalies (Cheung et al., 2011; Kovero et al., 
2006). These anomalies are divided into three categories: 1) platybasia meaning flattening 
of the skull base, 2) basilar impression where cranial base is lowered in relation to spine 
and the uppermost vertebral structures are located above the caudal border of the skull, 
and 3) basilar invagination where the uppermost vertebral structures protrude into the 
cranium through foramen magnum. These anomalies are separate but often coincide 
(Kovero et al., 2006). Chiari I malformation is a frequent comorbidity, a prevalence up to 
33-38% having been reported in patients with cranial base anomaly (Pindrik and Johnston, 
2015). The anomalies may cause compression of the brain stem or spinal cord and their 
related neurovascular structures, leading to disturbed circulation of the cerebrospinal fluid, 
vascular compromise, as well as sensory and motor dysfunctions (Menezes, 2008), even 
ending in most severe cases to the patient’s death (Sawin and Menezes, 1997). To prevent 
the most severe symptoms, neurosurgical treatment is in some extreme cases necessary 
(Hansen et al., 2008; Sasaki-Adams et al., 2008). Craniocervical anomalies, especially 
platybasia, can also be asymptomatic. Since platybasia usually occurs asymptomatically, 
its clinical significance has been questioned. A baseline cephalometric examination with 
lateral skull radiograph of all OI patients before school age has been recommended as a 
screening method for cranial base anomalies (Storhaug, 2002). An individually adjusted 
plan for follow-up and treatment of those patients with abnormal findings is then 
warranted (Arponen et al., 2012). MRI and CT are used for further evaluation of abnormal 
findings in lateral skull radiography, and MRI is the optimal modality for abnormalities of 
brain and spinal cord (Khandanpour et al., 2012). 
 
The most prominent dental aberration associated with OI is dysplastic dentin formation, in 
the literature, very often referred to as type I dentinogenesis imperfecta. The involvement 
of dentin is explained through type I collagen being the most important structural protein 






patients (Lukinmaa et al., 1987; Lund et al., 1998; Malmgren and Norgren, 2002; 
Schwartz and Tsipouras, 1984). The severity of dental findings is, however, rather a 
continuum, and hence milder aberration may remain underdiagnosed (Waltimo et al., 
1996). Dentinal abnormality is not associated strictly with any OI subtype, though the 
probability rises with the clinical severity of OI (Malmgren and Norgren, 2002). The color 
of affected teeth is typically yellow-brown or opalescent gray, but it may vary within the 
dentition, as well as between primary and permanent dentitions (O'Connell and Marini, 
1999). The permanent dentition is almost always less affected. Although enamel is 
normal, it tends to fracture easily due to abnormal dentin, leading to significant attrition in 
a short time-period in some patients. Full coverage crowning after the full eruption of the 
primary dentition is often used at least in the primary molar area to maintain the 
appropriate vertical dimension of occlusion. In the permanent dentition, the dental care is 
usually more conservative. Radiographic signs of dentinal abnormality include bulbous 
shape of crowns, cervical constriction, short and thin roots and over time obliterating 
pulpal chambers. The diagnosis is usually based on clinical and radiological findings, 
although some OI patients with clinically and radiographically normal teeth may display 
histologically abnormal dentin (Waltimo et al., 1996). In addition to structural dentin 
abnormality, OI patients also have an increased prevalence of hypodontia and 
malocclusions. The prevalence of hypodontia is reported to be as high as 20% (Lukinmaa 
et al., 1987; Malmgren et al., 2017). Typical malocclusion problems are class III 
malocclusion, anterior and posterior open bites, crossbites, and impacted teeth, and are 
more severe than in healthy individuals (Rizkallah et al., 2013; Eimar et al., 2016). The 
etiology of most of these malocclusion traits in OI resides in the vertical 
underdevelopment of the jaws (Waltimo-Siren et al., 2005). 
 
The majority of adult patients with OI have functional hearing loss. In the first two 
decades of the life, hearing loss is relatively infrequent and is mostly detected only as a 
subtle audiometric abnormality (Kuurila et al., 2000). It exceeds functional stage in some 
patients in early adulthood, and up to 50% of the patients older than 50 years, report 
hearing loss, pathological audiometric findings being even more common (Kuurila et al., 
2000; Paterson et al., 2001). The hearing loss related to OI is both conductive and 






results, but because of anatomic anomalies in the middle ear and tendency for profuse 
bleeding that are characteristic for OI, the operation is difficult (Kuurila et al., 2004). 
There are no long-term results about the benefits of cochlear implants, though short-term 
results are promising (Streubel and Lustig, 2005). 
2.3.4 Classification 
The clinical severity of OI is a continuum. However, in planning the treatment and 
rehabilitation as well as assessing the prognosis, categorization of the patient is necessary. 
Therefore, through the history, patients have been categorized in different ways. At the 
beginning of the 20th century, the patients were divided into two groups of OI: congenital 
and tarda, the first one being more severe and the latter milder with fractures only 
occurring after birth (Chawla, 1964). This classification was, however, inevitably 
inadequate for the clinical management of the patients. 
 
Thus, in 1979, Sillence and colleagues introduced a classification method for OI (Sillence 
et al., 1979), which is still in use, though with some modifications. The classification 
divided OI patients into four groups according to clinical characteristics and pattern of 
inheritance. The classification does not take genetic background into account, and since 
knowledge about the genetic background of OI has increased, there has been debate on the 
deficiencies of the classification. At first, when mutations in new genes causing OI were 
described, new subtypes were added to the classification, representing these patients. The 
number of these genes, however, has grown rapidly, and this practice has been questioned. 
The latest nomenclature recommends dividing OI in five groups (Van Dijk and Sillence, 
2014). 
 
Type 1 OI comprises patients with mild disease and is the most common of the subtypes. 
The patients exhibit relatively mild bone fragility, and they do not have significant bone 
deformities or height deficit. Vertebral compression fractures are, however, typical and 
can lead to scoliosis, though rarely. Almost all the patients with type 1 OI have distinctly 
grey-blue sclerae. Type 2 OI is the severest form and it is lethal during the perinatal 






The latter one causes respiratory failure, which is the major cause of death after birth. Of 
those patients, surviving the neonatal period, the severest form of OI is type 3. These 
patients have significant bone deformities and very short stature and suffer multiple long-
bone and vertebral fractures already prenatally or during the early stages of their life. 
Respiratory difficulties due to multiple rib fractures and severe kyphoscoliosis are the 
leading cause of death in this patient group as well. Sclerae are typically blue at birth but 
often become progressively whiter during life. The patients with moderate phenotype of 
OI are classified as type 4. These patients have moderately increased fracture incidence, 
mild to moderate bone deformities, and variably short stature. Sclerae are normally white, 
though some bluish hue may be seen at birth. This patient group is the most versatile, the 
severity typically varying even within families, some family members having considerably 
mild OI. The rarest subtype within this classification of OI is type 5. It is characterized by 
progressive calcification of the inter-osseus membranes in the forearms and legs, as well 
as by increased propensity to develop hyperplastic callus. Calcification of the inter-osseus 
membranes in forearms leads to restricted pronation and supination. Histomorphometric 
appearance of bone is characteristically coarse or mesh-like. The clinical severity is 
moderate and the sclerae normal. The causative genes for the OI types are listed in Table 




Bisphosphonates (BPs) were first synthesized in 1865 in Germany and since then they 
have been known by chemistry (Menschutkin, 1865). They were used in industry as 
corrosion inhibitors or as complexing agents in the branches of textile, fertilizer, and oil 
industry. It was not until the 1960s when medicine became interested in BPs. Fleisch and 
colleagues had earlier found that inorganic pyrophosphate, contained in plasma and urine, 
inhibits in vitro formation and dissolution of calcium phosphate crystals (Fleisch and 






might act as a local physiological regulator of calcification and decalcification (Fleisch et 
al., 1966). Because rapid hydrolysis precluded broader use of pyrophosphate as a 
therapeutic agent, Fleisch and colleagues turned to BPs that had similar physicochemical 
effect but resisted enzymatic hydrolysis. The first report about medical use of BPs was 
published in 1969 (Fleisch et al., 1969). 
2.4.2 Structure 
BPs are structural analogues of pyrophosphates where oxygen connecting the two 
phosphates is substituted by a carbon atom. The P-C-P backbone accounts for the high 
affinity of BP to hydroxyapatite. The P-C-P structure has two lateral chains (R1 and R2) 
that allow great variability, and it is these chains that are modified to synthesize different 
BPs. The first generation of BPs used pharmacologically, such as etidronate and 
clodronate, did not contain nitrogen. It was then, however, discovered that positioning a 
nitrogen atom in the R2-chain increases the pharmaceutical potency of the molecule by 10 
to 100 folds. To date, most of the BPs contain a nitrogen atom. The affinity of BP to 
hydroxyapatite can also be increased by adding a hydroxyl group (-OH) in the R1-chain. 
(Giger et al., 2013) 
2.4.3 Pharmacokinetics 
BPs are to date administered either orally or intravenously. The absorption of the oral BP 
through the gastrointestinal canal is limited, the average bioavailability being only 0.3 to 
7% (Ezra and Golomb, 2000). BPs chelate calcium in the gastrointestinal tract lowering 
even further the fraction of absorbed BP. In real life, food, drink, and cations decrease 
markedly the absorption, and BPs are hence recommended to be taken 30 minutes before 
breakfast (Ezra and Golomb, 2000). Approximately 50% of BP reaching the bloodstream 
is rapidly eliminated by the kidneys. The rest binds to the skeleton where it is not released 
from before the bone is resorbed. Therefore, their skeletal half-life is extremely long, up to 
several years (Giger et al., 2013). Only the non-nitrogen-containing BPs are metabolized 
to cytotoxic ATP analogues, others remaining intact. The main route of elimination is via 






2.4.4 Mechanisms of action 
The molecular mechanism of action of BPs remained long unknown but much has been 
learned recently. The two groups, nitrogen-containing and non-nitrogen-containing BPs 
affect osteoclasts though different pathways. When taken up by endocytosis into an 
osteoclast, nitrogen-containing BPs inhibit the mevalonate pathway of cholesterol 
synthesis, especially pharnesyl pyrophosphate synthase, the main enzyme of the pathway. 
Hence, they prevent phenylation of small GTPases, leading to inhibition of the formation 
of the ruffled border, membrane trafficking, and transcytosis of degraded bone matrix. 
They can ultimately induce apoptosis which seems not to be the main mechanism of 
action, however. (Eghbali-Fatourechi, 2014; Rogers et al., 2011) The non-nitrogen-
containing BPs are instead in osteoclasts incorporated metabolically into methylene-
containing ATP analogues. The osteoclasts cannot degrade these cytotoxic ATP 
analogues, and they condensate and accumulate in the cytosol of the cell, leading to 
apoptosis (Eghbali-Fatourechi, 2014). BPs have also been reported to inhibit apoptosis of 
osteoblasts and osteocytes at low concentrations (Plotkin et al., 1999). These effects on 
osteoblasts and osteocytes are, however, of markedly less significant than the direct effects 
on osteoclasts. Different BPs with their wide range of potency to inhibit bone resorption 
are shown in Table 3. 
 
Table 3: Characteristics of different bisphosphonates. Their relative potency to inhibit 
bone resorption in vitro is given, etidronate serving as a reference (Shaw and Bishop, 
2005). Administration depicts available routes of administration. 
 
Nitrogen-containing Administration Relative potency 
Etidronate No Oral 1 
Clodronate No IV/Oral 10 
Pamidronate Yes IV/Oral 200-500 
Olpadronate Yes Oral 200-500 
Ibandronate Yes IV/Oral 500-1,000 
Aledronate Yes Oral 1,000-2,000 
Risedronate Yes Oral 2,000 







2.5 Medical therapies in children with OI 
2.5.1 Bisphosphonates 
The first case report concerning BP treatment in a pediatric patient with OI was published 
in 1987 by Devogelaer and colleagues (Devogelaer et al., 1987). They reported notable 
clinical and radiological improvement in a 12-year-old female with OI after one year of 
oral pamidronate treatment. It took, however, until the late 1990s that larger observational 
studies about the benefits of BP treatments in pediatric patients with OI were published 
(Glorieux et al., 1998), and BPs started to become more common as part of the treatment 
of patients with OI. Nowadays, the use of BPs is widespread in children with OI, 
especially in its moderate to severe forms. However, since large double-blind randomized 
placebo-controlled studies with intravenously administered BPs are still lacking, the 
benefits of BP treatment have been questioned. For instance, in USA, BP treatment is not 
an indicated therapy for OI. 
 
A large number of observational studies have shown that during BP treatment children 
with OI experience a marked increase in BMD and bone mass (Glorieux et al., 1998; 
Lindahl et al., 2016; Rauch et al., 2003). They also suggest a decrease in fracture 
incidence (Glorieux et al., 1998; Lindahl et al., 2016; Plotkin et al., 2000) and an 
improved vertebral shape (Astrom et al., 2007; Land et al., 2006). Various aspects of the 
quality of life, such as bone pain, general well-being, and ability to perform in daily living, 
have also been shown to improve (Astrom and Soderhall, 2002; Land et al., 2006). The 
dentinal dysplasia is unaffected since no osteoclasts exist in developing or mature dentin. 
The studies have mostly comprised patients with moderate to severe OI, and thus the 
benefits of the treatment in milder forms are still unclear. The first studies were performed 
using intravenous pamidronate, which is still the most widely used BP in children. 
Recently, more potent intravenous BPs, zoledronic acid and neridronate, have however 
been increasingly used, mostly because of their less frequent administration compared 
with pamidronate. The results with zoledronic acid and neridronate have been similar to 
those with intravenous pamidronate (Barros et al., 2012; Gatti et al., 2005). The results of 
the only double-blind randomized placebo-controlled study are shown in Table 4, and do 






pain, or improvement in general well-being (Letocha et al., 2005). Obstacles to larger 
randomized trials include, however, lack of interest among patients and their families to 
risk being randomized to placebo, and lack of interest among clinicians who have 
experienced the benefits of BP treatment among their patients. 
 
In the last few years, double-blinded randomized placebo-controlled studies have 
demonstrated that also oral BPs have beneficial effects in children with OI. Oral 
risedronate and olpadronate increased BMD and reduced fracture risk (Bishop N et al., 
2013; Rauch et al., 2009; Sakkers et al., 2004). Oral alendronate was found to increase 
BMD in children with moderate to severe OI, but no significant decrease in fracture 
incidence was seen (Ward et al., 2011) (Table 4). Traditionally, oral BPs are customary to 
use in adult populations. Currently, oral BPs are, however, also used with pediatric 
patients with milder forms of OI. Another patient population propitious for oral BPs is 
those children suffering needle phobia or refusing intravenous BP treatment for some 
other reason. 
 
Histomorphometric and radiographic studies have shown that the main effect of BPs in 
growing patients with OI, i.e. the gain in bone mass, is due to increase in cortical thickness 
and trabecular number, while trabecular thickness and architecture remain unchanged 
(Rauch et al., 2002; Apolinário et al., 2016). Increase in cortical thickness resembles 
reduced osteoclastic activity in modeling; osteoblasts on the outer surface of cortex form 
new bone faster than osteoclasts on the inner surface resorb the older. The increase in 
trabecular number is instead due to a decrease in remodeling activity. The high 
mineralization stage characteristic of OI bone is found to remain unchanged (Weber et al., 
2006). The effect of BP treatment on intrinsic material properties of bone still remains 
unclear, studies with murine models and human patients reporting contradictory findings 
(Kashii et al., 2008; Shahnazari et al., 2010; Uveges et al., 2009). 


















































































































































































































































































































































































































































































































































































































































































The most common side effect reported with intravenous BPs is the typical acute-phase 
reaction with influenza-like symptoms. The reaction is characterized with fever, malaise, 
nausea, myalgia, and sometimes diarrhea (Glorieux et al., 1998; Hogler et al., 2004). 
Approximately 85% of the patients experience at least some of these symptoms in the first 
72 h after the first infusion. Reactions with the subsequent infusions are rare. Other 
common short-term side effects include transient hypocalcemia, hypophosphatemia, and 
rise in C-reactive protein, which rarely are symptomatic or of clinical significance. 
However, correction of possible preexisting vitamin D deficiency prior BP treatment, and 
supplementation of calcium before and after the first infusion are recommended (Bachrach 
and Ward, 2009; Hogler et al., 2004). As more severe acute phase responses, a few cases 
of respiratory failure during pamidronate infusion cycle have been reported in children 
with OI (Munns et al., 2004; Olson, 2014). The use of oral BPs has been associated in 
adults with chemical esophagitis and esophageal ulcerations. The understanding of proper 
administration, patient takes an adequate amount of water with medication and remains 
uprights for more than 30 minutes afterwards, have decreased these problems (Orozco and 
Maalouf, 2012). In children, the use oral BPs is not recommended for patients with risks 
for gastrointestinal disease, and for those receiving oral BPs, regular monitoring for  
gastrointestinal symptoms are suggested (Boyce et al., 2013). 
 
Since BPs remain in the body for years and experimental studies have shown them to 
cross the placenta, a concern has been that BPs would also effect developing fetus. 
Moreover, in animal models, they have been associated with skeletal anomalies in 
offspring (Patlas et al., 1999). However, human reports concerning women exposed to 
BPs before conception or during pregnancy did not demonstrate serious adverse effects to 
fetuses. Since the experience is, however, scarce, it has been recommended that BP 
treatment should be discontinued 6 to 12 months before conception (Suresh et al, 2014). 
 
One of the adverse effects associated to BPs that has attracted much attention in adults is 
osteonecrosis of the jaw. It has usually occurred in older patients undergoing BP 
treatment, usually intravenously administered, for malignant disease or osteoporosis, and 
associated strongly with invasive dental procedures. The reducing effect on bone turnover 






and therapy-resistant process (Kumar and Sinha, 2014). Despite the large studies and 
general concern, no cases of osteonecrosis of the jaw have been reported in children with 
OI treated with BPs (Hennedige et al., 2013). Nonetheless, it has been suggested that all 
children should have a dental check-up with required dental procedures prior to the onset 
of BP treatment (Bhatt et al., 2014). Since bone resorption is crucial to tooth eruption, it 
has been suggested that BPs would delay eruption of teeth. Animal models support this 
hypothesis (Grier and Wise, 1998), but evidence supporting it in human still remains 
scarce (Kamoun-Goldrat et al., 2008). Furthermore, studies with animal models also 
suggest BPs to have detrimental effect on orthodontic therapies by slowing down the 
attended tooth movement (Iglesias-Linares et al., 2010). The clinical significance of these 
findings yet remains unclear. 
 
BPs have been found to interfere with growth plates, causing radiographically seen dense 
transverse lines in the metaphysis in every infusion. These sclerotic lines consist of 
cancellous bone that contains calcified cartilage (Rauch et al., 2004). BPs can also impair 
normal metaphyseal inwaisting, leading to club-shaped deformities and undertubulation in 
metaphyses, although this finding was seen in a patient exposed to doses exceeding 
markedly the recommended treatment doses (Whyte et al., 2003; Whyte et al., 2008).  
 
Since BPs reduce remodeling activity of bone, a general concern has been that especially 
long-term use of BPs reduces it to a stage where microcracks can accumulate and lead to 
stress fractures. This phenomenon has been seen in adult patients with osteoporosis treated 
with BPs, especially after prolonged use (Gedmintas et al., 2013). The typical location of 
these stress fractures is the subtrochanteric region of the femur, and the fractures are called 
atypical femoral fractures (AFF). Some case reports concerning AFFs in adult OI patients 
have been published (Etxebarria-Foronda and Carpintero, 2015; Holm et al., 2014; 
Manolopoulos et al., 2013; Meier et al., 2012), but it is still unclear whether growing 
children have similar problems. Recently, a case report emerged, however, reporting a BP-
treated teenager with OI who sustained recurrent femoral fractures with features of AFF 
(Vasanwala et al., 2016). One larger study has also evaluated this aspect in pediatric OI 
patients and suggests a changing pattern in femoral fractures associated with BPs 






it has been speculated whether BP treatment interferes with it. The studies concerning the 
topic suggest delayed bone healing after osteotomy but not after fracture in association 
with BP treatment (Munns et al., 2004; Pizones et al., 2005). A more recent follow-up 
study reported markedly reduced incidence of delayed osteotomy healing, which may have 
at least partially attributed to changes in BP infusion protocol (infusions were not given 
for four months after the operation) (Anam et al., 2015). Whether BPs should be ceased, 
and for how long, after osteotomy or acute fracture remains unclear. Contrary to concerns 
about adynamic bone, related to prolonged BP treatment, the cessation of BP treatment 
during growth leads to lowered levels of metaphyseal bone mineral in subsequently 
formed bone and increased risk of fractures in the junction of the treated and untreated 
bone (Rauch et al., 2006). The question whether “drug holidays”, a cessation of BP 
treatment, or maintenance treatment with either less frequent cycles of intravenous BPs or 
with oral BPs would be safer and more beneficial, is still unclear and needs further studies. 
2.5.2 Other medical treatments 
Another anti-resorptive therapy for OI is denosumab. It is an antibody against RANKL, a 
cytokine crucial to osteoclastogenesis and osteoclast function (Lacey et al., 1998). At a 
histological level, denosumab and BPs have similar effects on growing bone (Wang et al., 
2014). Denosumab has established its role in treatment of postmenopausal osteoporosis 
and other skeletal disorders in adults, but the experiences in children with OI are scarce 
(Hoyer-Kuhn et al., 2016; Semler et al., 2012). The advantage of denosumab compared 
with BPs is its much shorter duration of action, allowing better control.  
 
Therapies with bone-anabolic agents have attracted general interest, especially since 
genetic defects underlying OI primarily affect osteoblasts. Teriparatide (recombinant 
human PTH) has been shown to stimulate bone formation and have a beneficial effect on 
BMD in adult patients with mild OI. The effect was, however, less obvious in patients 
with moderate to severe OI (Orwoll et al., 2014). There is concern about neoplastic risk in 
children related to teriparatide, and no evaluation of its use in children with OI has been 
published. Antibody-mediated sclerostin inhibitors are a new approach to stimulate bone 






to teriparatide in adults with OI, sclerostin-inhibiting therapies have shown more promise 
with mouse models for mild OI than in mouse models for severe OI (Roschger et al., 
2014; Sinder et al., 2013). It has been suggested that the reason for the less impressive 
results of bone anabolic agents in more severe OI is due to the already increased bone 
formation rate, characteristic of these patients (Trejo and Rauch, 2016). In addition to 
specific bone anabolic agents, growth hormone stimulates osteoblasts as well. Findings of 
small studies suggest that growth hormone therapy has an increasing effect on BMD and 
linear growth in children with OI (Antoniazzi et al., 1996; Marini et al., 2003), but the 
results are, modest at the best. Furthermore, no data on its beneficial effect on final adult 
height or fracture incidence have been published. 
 
Adequate intake of calcium and vitamin D is important for children with OI, especially 
since the serum 25-hydroxyvitamin D concentration is independently associated with 
BMD (Edourdo et al., 2011). High-dose vitamin D (2000UI) did not, however, prove to be 
better to low-dose vitamin D (400UI) in increasing lumbar spine BMD (Plante et al., 
2016). Calcium and vitamin D-rich food and proper supplementations are hence 






3 Aims of the Study 
BPs are commonly used in the treatment of pediatric patients with OI. Much of their 
impact on the bone of growing children remains unclear, and there are still many general 
concerns regarding especially their long-term effects. The aim of this thesis was to 
evaluate the benefits and long-term safety of BP treatment in children with OI, as well as 
assess the use of zoledronic acid instead of most commonly used intravenous BP 
pamidronate in the treatment of children with mild OI. 
 
The following specific aims were set for the present study: 
 
1 To assess the efficacy and short-term safety of zoledronic acid, an intravenous 
BP, in pediatric patients with OI. 
2 To study the association of BP treatment with the morphology of the cranial base 
and craniocervical junction, as well as with the development of cranial base 
pathology in growing OI patients. 
3 To study the association of BP treatment with the characteristics of femoral 
fractures in children with OI. 
4 To study the association of BP treatment during childhood with the development 
and eruption of the permanent teeth, as well as resorption of the primary teeth in 
children with OI.  
 
The hypotheses were: 
 
1 Zoledronic acid is an effective treatment in children with OI. 
2 BP treatment is associated with decreased risk to develop cranial base pathology 
in children with OI. 
3 BP treatment is associated with changed characteristics of femoral fractures in 
children with OI. 
4 BP treatment is associated with delayed dental development and eruption of 






4 Materials and Methods 
4.1 Patients and controls 
The study population of all four studies comprised children and adolescents with 
diagnosed OI followed at the Metabolic Bone Clinic, Children's Hospital, Helsinki 
University Hospital, Finland. The clinic is responsible for coordination of patient care in 
moderate to severe OI, and for planning and follow-up of medical treatment of all 
pediatric OI patients in Finland. Currently, approximately 90% of the Finnish pediatric OI 
patients are or have been under follow-up at the hospital. 
4.1.1 Study patients 
Inclusion criteria for patients: 
STUDY I (efficacy and safety of zoledronic acid): (i) Diagnosis of mild OI, (ii) 
treatment with intravenous zoledronic acid, (iii) a minimum treatment duration of 12 
months, and (iv) no prior BP treatment. 
STUDY II (BPs and cranial base pathology): (i) Diagnosis of OI, (ii) treatment with BP 
during growth, (iii) availability of radiographic evaluation of the cranial base during or 
after BP treatment, and (iv) age under 25. 
STUDY III (BPs and femoral fractures): (i) Diagnosis of OI, and (ii) born between 
1990 and 2012.  
STUDY IV (BPs and dental development/tooth eruption): (i) Diagnosis of OI, (ii) age 
between 3 and 16 years, and (iii) treated with BPs for a minimum period of one year. 
 
Study IV included patient recruitment. Altogether 39 patients fulfilled the inclusion 
criteria. These patients were contacted by mail and phone, and 17 patients consented to 
participation of clinical evaluation and radiography, the most common reasons for not 
participating being lack of time or interest. One of the consented patients was not able to 
follow the study protocol due to current health problems and was since excluded from the 
study group. In addition, six patients not taking part in the clinical examination were 
included into the study group using already available data. 





















































































































































































































































































4.1.2 Bisphosphonate treatment 
The BP treatment of each patient in the Metabolic Bone Clinic is individualized based on 
clinical features and symptoms, including sustained fractures and BMD. For the 
intravenously administered BPs, the annual dose/kg is standardized, but the infusion 
protocol depends on the age and disease severity of the patient. Most of the patients 
receive intravenous pamidronate (9 mg/kg/year divided into 3 to 12 1-3-day infusion 
cycles per year, depending on age and disease severity) or zoledronic acid (0.1 mg/kg/year 
divided into 2 to 4 infusions per year). A few patients with mild OI receive orally 
administered risedronate (2.5 mg/day for patients weighing 10-30 kg, and 5 mg/day for 
patients weighing over 30 kg). A “drug holiday” of at least one year was kept after 2 to 3 
years of BP treatment. The patients were monitored at least yearly, and BP was restarted if 
BMD deteriorated or pain or new fractures occurred. 
 
The concept of cumulative dose was applied to compare various treatments with different 
lengths and different BPs. It was expressed per body weight (mg/kg), and coefficients 
were used due to three different BPs. These coefficients, introduced by Shaw and Bishop 
(Shaw and Bishop, 2005), are based on the relative potency of the molecules to in vitro 
inhibit bone resorption (Table 3). The low bioavailability of orally administered 
risedronate (0.63%) was also taken into account. 
4.1.3 Control groups 
To assess the effect of BP treatment, control groups were included in Studies II and IV. In 
Study II, the control group comprised historical data of 70 patients with OI, who were 
aged between 0 and 39 years and were not treated with BP. It was used only in the 
longitudinal analysis. In Study IV, 50 patients with OI, aged 3 to 16 years, comprised the 
control group of OI patients naïve to BPs. In addition, regarding one parameter, the 
resorption of deciduous teeth, no reference values were available and historical data of 
randomly chosen 50 healthy Finns (aged 5 to 14 years) served as normal reference to 







4.2.1 Data collection 
Studies I, II, and III were retrospective cohort studies. In these studies, the data was 
retrospectively collected from patient records. The noteworthy data included height and 
medication data (Studies I, II, and III), fracture history (Studies I and II), neurological 
status and symptoms (Study II). For all femoral fractures, data were also collected 
regarding potential presence of intramedullary roding and the trauma energy leading to 
fracture (Study III).  
 
Study IV was a cross-sectional study. Altogether 16 consented patients went through the 
clinical examination, and a dental panoramic tomograph (DPT) was obtained if one was 
not available within 3 years (12 patients). In addition, DPTs taken within 3 years of six 
additional patients who did not take part in the clinical evaluation were included in the 
analysis. The presence or absence of dentinal abnormality was assessed using clinical and 
radiologic criteria. Patient records were used for medication data. 
4.2.2 Biochemical measurements (Study I) 
The effect of zoledronic acid on bone turnover was determined using biochemical 
markers. Plasma ALP and serum PINP were used as markers of bone formation, while 
serum ICTP and urine NTx represented bone resorption activity. These markers were 
analyzed at the baseline and then semi-annually during the treatment, taking the last 
sample 6 months after the last infusion. To assess the short-term safety of zoledronic acid, 
the analysis included blood and urine samples obtained at the onset of each infusion and 6 
months after the last infusion for parameters of calcium homeostasis, liver and renal 
function, and blood cell count. In addition, plasma concentration of calcium was measured 
2 h after every infusion, and that of phosphate and parathyroid hormone 2 days later, to 






4.2.3 Densitometry (Study I) 
BMC and bone area at the lumbar spine, femoral neck, and whole body were measured at 
the baseline and then annually with DXA to evaluate the changes in areal BMD (aBMD) 
(g/cm²). Measurements were performed using Hologic Discovery A, using pediatric 
software version 12.4. All values were transformed into z-scores using age- and sex- 
specific reference data for the equipment. To also take the shape of lumbar vertebrae into 
account, additional lateral projection of lumbar spine was obtained with DXA scanner, and 
volumetric BMD (vBMD) (g/cm³) values were automatically calculated. For vBMD, no 
pediatric reference values were available. 
4.2.4 Vertebral assessment (Study I) 
The effect of zoledronic acid on development and healing of vertebral fractures was 
evaluated using conventional postero-anterior and lateral radiographs of the thoracic and 
lumbar spine. The morphology of each lumbar and thoracic vertebra was individually 
assessed using a standardized pediatric scoring system (Makitie et al., 2005), regarding 
20% or greater reduction in vertebral height abnormal. The spinal fractures were classified 
as anterior wedge deformities if anterior and middle vertebral heights were decreased as 
compared with the adjacent normal vertebrae. If anterior, middle, and posterior vertebral 
heights were all decreased, the classification was compression deformity. 20 to 49% of 
reduction was considered mild and the reduction of 50% or more severe. The 
improvement or deterioration of spinal changes was determined by comparing the grades 
assigned to each vertebra at treatment baseline and after 2 years of treatment. 
4.2.5 Measurements of cranial base anatomy (Study II) 
Lateral skull radiographs (94) and midsagittal MR (2) images were used to perform cranial 
base measurements. The three independent measurements (anterior cranial base angle, D-
M angle, and McRae’s measure) were calculated using 6 cephalometric landmark points 
(Figure 3). The reliability and applicability of the method for screening of basilar 
pathology has previously been reported by Arponen and colleagues (Arponen et al., 2008). 






of healthy ethnic Finns were used as reference (Arponen et al., 2008; Arponen et al., 
2010; Arponen et al., 2012).  
 
Figure 3: Cephalometric landmarks and reference lines. The illustration presents normal 
anatomy of cranial base structures. N = nasion, S = sella turcica, Ba = basion, Op = 
opisthion, D = dens (odontoid process), M = M-point. 1 = anterior cranial base angle, 2 = 
D-M angle, 3 = McRae’s measure. 
 
Cranial base measurements (Figure 3): 
1) Anterior cranial base angle: The angle between the nasion-sella and basion-sella 
lines. 
2) D-M angle: The angle between the line running thought the lowest point of the 






the tip of the odontoid process to the lowest point of the occipital curve (normally 
negative). 
3) McRae’s measure: perpendicular distance of the tip of the odontoid process to the 
foramen magnum line, basion-opisthion (normally negative). 
 
Following definitions and diagnostic criteria were used when evaluating cranial base 
anomalies: 
- Platybasia: Anterior cranial base angle >2.5 SD above the average age-specific 
reference values. 
- Basilar impression: D-M angle >2.5 SD above the average age-specific reference 
values. 
- Basilar invagination: McRae’s measure at zero or positive. 
4.2.6 Characterization of femoral fractures (Study III) 
The pattern of femoral fractures was assessed by characterizing the fractures according to 
the location of the fracture line within the femur, and fracture type by the shape of the 
fracture line. The assessment was performed using radiographs leading to fracture 
diagnosis. The location of fractures was categorized into four groups: 1) proximal 
fractures, including femoral neck fractures, intertrochanteric fractures, and slipped capital 
femoral epiphysis; 2) subtrochanteric fractures comprising the proximal third of the 
femoral shaft (diaphysis); 3) femoral shaft fractures comprising the mid and distal thirds 
of the femoral shaft; 4) distal fractures of femur comprising the fractures of distal 
metaphysis, physis, and epiphysis. Because of the rarity of other fracture types than 
transverse and oblique, the fracture type was categorized only into three groups: 1) 
transverse, 2) oblique, and 3) other fractures, which included fractures not fitting to these 







4.2.7 Methods to assess dental development (Study IV) 
The developmental status of the permanent teeth, grade of resorption of the primary teeth 
and status of eruption of the permanent teeth were analyzed separately using DPTs.  
 
The development of permanent teeth was assessed using the method introduced by 
Demirjian et al. (Demirjian et al., 1973), which determines dental age by evaluating the 
radiographic appearance of seven permanent left mandibular teeth from the central incisor 
to the second molar. If one of the index teeth was missing or could not be evaluated for 
any other reason, the analysis was supplemented by the corresponding right-side tooth. 
The method is based on the progressive mineralization of each index teeth that is divided 
into eight stages (A-H). Stage A corresponds to the start of mineralization when only cusp 
tips are mineralized, and H to the end point of mineralization when the tooth is fully 
mineralized up to the root apex. To evaluate the difference from normal development, 
weighted norms for Finnish boys and girls were used (Chaillet et al., 2004) and the 
assessed dental age, when differing from the chronological age by more than twelve 
months, was considered delayed or accelerated. 
 
The assessment of the resorption stage of the primary teeth was performed based on the 
method introduced by Haavikko (Haavikko, 1973) with some modifications. In technique 
of the present study, the stage of resorption was divided into four categories according to 
the length of the root. The stages were: 1 = full root present, 2 = a quarter of the root 
resorbed, 3 = half of the root resorbed, and 4 = the root completely resorbed. Already 
exfoliated teeth were scored as 4. The resorption stage was assessed for each five primary 
teeth in the left mandibular quadrant, and the scores were summed up to form a resorption 
sum score, ranging from 5 to 20. 
 
The eruption of the permanent teeth was assessed radiographically, and similarly limited 
to left mandibular quadrant. A tooth was considered emerged if it had pierced the alveolar 
bone cortex, whether or not it had pierced the oral mucosa. The number of erupted teeth 
was counted and compared with the published norms for timing of tooth eruption in 







4.2.8 Statistical methods 
With the continuous parameters, the differences between two groups were tested for 
significance using Student’s t-test or Mann-Whitney U test, and differences between two 
related samples using Student’s paired t-test or Wilcoxon signed-rank test, as appropriate. 
Analysis of variance was applied when comparing continuous variables in more than two 
groups. Categorical variables were tested with Chi-square test or Fisher’s exact test, as 
appropriate. Correlations between two different variables were tested with Pearson’s 
correlation analysis or Spearman’s rank correlation. Generalized linear mixed model was 
used to analyze the association between patient characteristics and cranial base anomalies. 
 
Statistical analysis was performed using StatView software (StatView 5.0.1; 1992-1998©; 
SAS Institute Inc., Cary, NC, USA) (Study I), the R-language (version 2.13.0, R 
Development Core Team, R: A Language and Environment for Statistical Computing 
(Vienna, Austria, 2008) (Study II), or SPSS software for Windows (versions 18 and 22; 
SPSS Inc., Chicago, IL, USA) (Studies II, III, and IV). 
4.2.9 Ethical considerations 
The studies were approved by the Research Ethics Committee, Children’s Hospital, 
Helsinki University Hospital. Informed consent was obtained from all the participants and 
their parents/guardians of Studies II and IV, which included imaging for scientific 
purposes. The imaging was always also clinically justified and the radiation exposure was 
considerably low. Studies I and III were retrospective cohort studies and hence the patients 







5.1 Efficacy and safety of zoledronic acid 
5.1.1 Efficacy 
A total of 17 patients with type 1 OI and previously naïve to BPs had been treated with 
zoledronic acid in our clinic by 2009 (Table 5). Their median age at treatment onset was 
10.1 years (range 1.5 to 16.8 years), and median treatment time 23 months (range 12 to 38 
months). At the onset of treatment, these patients had a history of in total 73 peripheral 
fractures during their life time, making the fracture incidence in this cohort 0.52 per year. 
During the last 2 years preceding the treatment, the mean fracture incidence was 0.38 per 
year. After the treatment onset, the patients sustained altogether ten new peripheral 
fractures, making their mean fracture incidence during follow-up 0.28 per year. However, 
the decrease (p=0.06) in this cohort did not reach the level of statistical significance. 
When considering vertebral fractures, nine patients (53%) displayed compressed vertebral 
bodies in baseline spinal radiographs. Follow-up radiographs obtained after 24 months of 
treatment were available for nine patients. Of them, five had had compression fractures 
already at baseline and one additional patient manifested with a compression at follow-up. 
Of the five patients with compression fractures at baseline, two had new compressions at 
follow-up. However, three patients had fewer compressions than at baseline. At the onset 
of treatment, three patients suffered daily bone pain. After the treatment onset, two of 
them reported that pain disappeared. In one these two patients, the infusion interval was 
shortened to 3 months in order to prevent re-occurrence of pain. 
 
At the treatment onset, the median lumbar spine aBMD z-score, for 14 patients whom it 
could be measured, was -2.0, and during the first treatment year, it improved to -1.0 
(p<0.001). The improvement was more moderate during the second treatment year: for 
those ten patients who completed the 2 years of treatment, the median lumbar spine z-
score improved from -2.3 to -1.2 (p<0.001) during the first treatment year, and from -1.2 
to -0.7 (p=0.01) during the second treatment year. The aBMD values measured at whole 






markers of both bone formation (plasma ALP and serum PINP) and bone resorption (urine 
NTx) showed a marked decrease in bone metabolism during the first six months of the 
treatment and stayed reasonably stable after it. During the first six months of the 
treatment, the average decrease in plasma ALP was 17% (p<0.01), in serum PINP 43% 
(p<0.001), and in urine NTx 46% (p<0.01). The second marker of bone resorption (serum 
ICTP) did not show a statistically significance difference during the treatment (Figure 5). 
 
Figure 4. Areal bone mineral density z-score at lumbar spine and whole body measured at 
baseline and after 12 and 24 months of zoledronic acid treatment. The plot shows median, 









Figure 5: Biochemical markers of bone metabolism, serum alkaline phosphatase (S-ALP) 
and plasma procollagen type I N-terminal propeptide (P-PINP) referring to bone 
formation, and serum collagen type I C-terminal telopeptide (S-ICTP) and urine collagen 
type I N-terminal telopeptide (U-NTx) referring to bone resorption. The values are shown 
at baseline and after 6, 12, and 24 months after zoledronic acid treatment. The numbers 








Overall, the treatment was well tolerated. The most common side effect was transient flu-
like reaction after the first infusion that occurred in 11 out of 17 patients (65%), 5 of 
which reported bone pain as well. Only one patient had the same reaction after the second 
infusion. Plasma calcium values measured 2 days after the first infusion and the mean 
decrease after the first infusion was 9% (p<0.001). 12 patients had values below normal, 
of whom 2 had clinical symptoms, mainly fatigue, dizziness, nausea, and mild muscle 
tremor. These two patients were treated with intravenous calcium and the symptoms 
improved. Similar decrease in calcium levels was seen with subsequent infusions but 
without clinical symptoms (mean decrease 7-10%, p<0.001). The mean plasma phosphate 
decreased 41% (p<0.001) after the first infusion. After subsequent infusions, the decrease 
was between 20 and 32%. All changes were transient and normalized by the time of the 
next infusion. 
5.2 Cranial base pathology 
The study group comprised altogether 39 pediatric patients with OI representing a wide 
spectrum of severity (Table 5). Of these patients, 13 (33%) exhibited a cranial base 
anomaly, platybasia being the most prevalent diagnosis (28%). The prevalence of basilar 
impression was 18% and basilar invagination 15%. Logistic regression analysis suggested 
that a higher risk for basilar impression and basilar invagination correlated with the 
severity of OI (type 3, OR 22.04, 95% CI 1.26-386.28, p=0.04). 
 
The cross-sectional analysis also suggested that a higher risk for basilar impression and 
basilar invagination correlated with older age at the onset of BP-treatment (OR 1.45, 95% 
CI 1.01-2.09, p=0.04) and short duration of the treatment (OR 0.28, 95% CI 0.087-0.09, 
p=0.03). No statistically significant association between cumulative BP dose and cranial 
base anomaly was detected. 
 
Longitudinal radiographic/MRI data were available for 22 patients (56%), of which 8 
patients exhibited at least one cranial base anomaly before the onset of BP treatment. Of 






any other anomaly during the follow-up. Of those four with persistent cranial base 
anomalies, one acquired additional basilar impression and platybasia, and one additional 
basilar impression and invagination. All basilar impressions and invaginations persisted 
during the follow-up. Five patients not displaying any cranial base anomaly at the onset of 
BP treatment developed one during the follow-up period. 
 
Kaplan-Meyer analysis showed a statistically non-significant trend towards delayed 
development of cranial base anomalies in patients treated with BPs when compared with 
BP-naïve patients (basilar impression, log rank = 0.205 on 1 df, p=0.651; platybasia, log 
rank = 0.326 on df, p=0.568). None of the eight patients whose BP treatment was started 
before the age of 3 years developed later basilar impression or invagination during the 
follow-up.  
5.4 The pattern of femoral fractures 
Altogether, 149 femoral fractures had occurred to 25 OI patients during the study period. 
For 127 fractures that had occurred to 24 patients, data were sufficient and formed the 
final research material. The basic demographics of these 24 patients are illustrated in 
Table 5. 
 
Among the 127 femoral fractures, the most common fracture site was mid or distal shaft 
(41%) followed by subtrochanteric and distal fractures, respectively. Regarding the 
fracture type, transverse fractures comprised approximately two thirds of all fractures. The 
remaining third were mostly oblique by configuration, other fracture types being rare (7%) 
(Figure 6). Analysis of the femoral fractures in the various OI subtypes revealed some 
statistically significant differences in fracture site: Distal fractures were more common in 
the more severe types 3 and 4 OI compared to the milder type 1 OI, whereas fractures of 
the mid or distal femoral shaft were more common in type 1 OI than in types 3 and 4 
(Table 6). 
 
Regarding BP treatment, 50% of the fractures had occurred in patients naïve to BPs, 35% 






and fracture type was similar in all above mentioned groups, and no statistically 
significant associations could be found between BP treatment and the pattern of femoral 
fractures, either (Table 6).  






























































































































































































































































































































































































































































































Figure 6: Examples of different fracture types. (A) An oblique fracture of the distal 
femur, shown by the white arrows, occurred in a 3.3-year-old girl with an ongoing 
bisphosphonate (BP) treatment. (B) A spiral fracture of the distal femur, shown by the 
white arrow, occurred in a 10.0-year-old boy naïve to BPs. (C) A comminuted fracture of 
the femoral shaft occurred in a 10.1-year-old boy with an ongoing BP treatment. (D) An 
epiphyseolysis of the proximal femur, shown by the arrow, occurred in a 12.8-year-old girl 
with an ongoing BP treatment. (E) A spiral fracture in the subtrochanteric region of the 
femur occurred in a 7.0-year-old boy with an ongoing BP treatment. (F) A transverse 
fracture of the femoral shaft occurred in a 7.0-year-old boy naïve to BPs. 
A B C 






5.3 Dental development 
A total of 22 patients treated with BP:s comprised the final study group. Their dental 
development, in terms of radiologically assessed developmental stage of the permanent 
teeth, resorption of the deciduous teeth, and number of erupted permanent teeth, displayed 
age-appropriate stage when compared with healthy Finnish children (p=0.23, p=0.23, and 
p=0.80, respectively). When the patients were divided into two groups according to the 
presence dentinal abnormality, the development was still age-appropriate (Table 7). 
 
Table 7: The difference between dental and chronological age in children with 
osteogenesis imperfecta, subgrouped by bisphosphonate treatment (BP) and dentinal 
abnormality (DI). Results are given as mean (range). 
 
 
When OI patients naïve to BPs were compared to healthy individuals, they were advanced 
in terms of development of permanent teeth and number of erupted permanent teeth 
(p=<0.001 and p=0.03, respectively). In the subgroup of patients with dentinal 
abnormality, the difference seemed to be even more evident (Table 7). In terms of 
resorption of the deciduous teeth, they did not differ statistically significantly from Finnish 
norms. 
 
When the two BP groups were compared with each other, OI patients naïve to BPs were 
found to be advanced in terms of resorption of the deciduous teeth when age was used as 
covariate (p=0.04) (Figure 7). In BP-treated OI patients, as in healthy controls, root 
resorption in the deciduous tooth never began until the crown of the underlying permanent 
tooth was fully complete, whereas in 27% of the OI patients naïve to BPs, the resorption 
n 
Difference between dental 
and chronological ages (y) p-value 
Difference between number of 
erupted teeth and reference values p-value 
BP+/DI- 17 +0.37 (-1.49 - +3.89) 0.47 -0.18 (-2 - +1) 0.32 
BP+/DI+ 5 +0.43 (-1.17 - +1.46) 0.35 +0.80 (0 - +2) 0.10 
Total/BP+ 22 +0.39 (-1.49 - +3.89) 0.23 +0.05 (-2 - +2) 0.80 
BP-/DI- 31 +0.58 (-2.03 - +3.77) <0.01 +0.29 (-3 - +3) 0.19 
BP-/DI+ 19 +0.93 (-1.43 - +3.77) <0.01 +0.42 (-1 - +2) 0.03 
Total/BP-  +0.71 (-2.03 - +3.77 <0.001 +0.31 (-3 - +3) 0.03 
Total/DI- 48 +0.51 (-2.03 - +3.89) 0.01 +0.13 (-3 - +3) 0.39 






started earlier. The difference in the developmental stage of the permanent teeth and the 
number of erupted permanent teeth was statistically non-significant (p=0.21 and p=0.23, 
respectively).  
 
Neither treatment time nor relative cumulative dose correlated with the rate of dental 
development, resorption of primary teeth or eruption of permanent teeth (p<0.05). 
 
 
Figure 7: Correlation between age and resorption sum score. The resorption sum score 
was statistically significantly different between the three groups (p=0.04). The difference 
was statistically significant between osteogenesis imperfecta (OI) patients naïve to 
bisphosphonates (BPs) and those treated with BPs (p=0.04), but not when either group 







6.1 Zoledronic acid treatment in children with mild OI 
Traditionally, intravenous pamidronate has been the most commonly used BP in the 
medical treatment of children with OI. The superior potency and longer-lasting efficacy in 
suppressing bone resorption give zoledronic acid, compared with pamidronate, however, 
an advantage in terms of infusion protocol. In  the clinic where the study was performed, 
the standard protocol of administration of zoledronic acid is one infusion over 45 min 
once every 6 months, which, compared with pamidronate given over 4 h in 3 successive 
days once every 4 months, makes it much more convenient to the families. 
 
In the present study, children with mild OI showed a marked improvement in aBMD 
during the first year of zoledronic acid treatment. During the second year of treatment, the 
improvement was approximately halved. The improvement did not reach the level of 
improvement reported in other studies on pamidronate (Arikoski et al., 2004; Glorieux et 
al., 1998; Rauch et al., 2003). However, the pretreatment BMC has been shown to 
negatively correlate with the increase in BMC during treatment (Rauch et al., 2003). 
Previous studies on pamidronate have predominantly included patients with moderate to 
severe OI, and thus, the explanation for the different levels of improvement could reside in 
the baseline. Furthermore, the improvement in BMD was slightly more favorable in the 
present study as compared with the findings of a study on pamidronate comprising only 
patients with mild OI (Zacharin and Kanumakala, 2004). Similar findings were later 
reported by Barros and colleagues in an open-label, prospective, and randomized clinical 
trial, comparing 1-year treatments with zoledronic acid and pamidronate (Barros et al., 
2012).  
 
The primary clinical outcome of BP treatment is fracture reduction. The present study 
suggested a decreasing trend in the fracture incidence during the treatment, but it was, 
however, statistically non-significant. Yet, it should be noted that since the susceptibility 
to suffer fractures varies considerably during the childhood in OI, the comparison to 






patients with vertebral compression fractures showed recovery during the treatment. On 
the other hand, new vertebral compressions were also diagnosed after 2 years of treatment, 
one occurring in a patient with no former history of compressed vertebrae. The 
radiographic evaluation of vertebral fractures in patients with OI is, however, challenging 
due to low BMD. Since some of these compressions were asymptomatic, it is possible that 
that those compressions only became radiographically more visible during the treatment. 
A similar pattern of progress was seen in other the studies on pamidronate (Astrom et al., 
2007; Land et al., 2006). 
 
Zoledronic acid treatment was overall well tolerated, and none of the patients discontinued 
the treatment because of side effects. The most common side effect was the “acute-phase 
reaction” with fewer and bone pain, characteristic of intravenous BPs. The reaction 
appeared only with the first infusion in all except one patient and was controlled with 
standard doses of acetaminophen. As with pamidronate treatment, significant changes in 
mineral homeostasis were detected after infusion but all these changes were transient and 
normalized by the subsequent infusion (Glorieux et al., 1998). Two patients suffered 
clinically symptomatic hypocalcemia, however, and required treatment with intravenous 
calcium, which has not been reported with pamidronate. These findings underline the 
importance of adequate calcium and vitamin D supplementation before and during 
zoledronic acid treatment. 
6.2 Long-term effects of BP therapy in children with OI 
6.2.1 Cranial base pathology 
Cranial base pathology is one of the most severe complications in OI, being in severe 
cases even life-threatening. Its prevalence increases hand in hand with the severity of OI 
(Cheung et al., 2011; Sillence, 1994). In the perinatally lethal type 2 OI, it is, however, not 
seen (Sawin and Menezes, 1997).The pathogenesis of basilar impression and invagination 
in OI is believed to involve a combination of bone fragility and malleability, as well as 
ligamentous hyperlaxity, which decreases the ability of the cranial base to resist the 






cervical spine migrates upwards in relation to the cranium. This theory is supported by the 
findings reported by Arponen and colleagues that basilar impression and invagination are 
detected only after the age of 2 years (Arponen et al., 2012). The observations in the 
present study were also consistent with this. 
 
In the cross-sectional analysis in the present study, the prevalence of cranial base 
pathology in the BP-treated children with OI was similar to the one found in a previous 
study on children with OI naïve to BPs, representing comparable distribution of clinical 
severity (Arponen et al., 2012). In the longitudinal analysis, a non-significant trend 
towards delayed progression of cranial base pathology was also seen in the Kaplan-Meier 
curves in patients treated with BPs compared to the historical control group naïve to BPs. 
It is obvious that hyperlaxity of ligamentous structures plays a prominent role in the 
pathogenesis of cranial base anomalies in OI. It should be noted that BP treatment does 
not affect these structures because of the absence of hydroxyapatite. Also, the observation 
that none of the eight patients in whom the BP treatment was started before the age of 3 
years developed basilar impression or invagination indicates that the early onset of BP 
treatment may have a favorable effect on the development of cranial base pathology. 
 
Platybasia, a flat skull base, may instead be present already at birth. Since it often occurs 
asymptomatically, its clinical significance has been disputed (Botelho and Ferreira, 2013). 
However, platybasia has been associated with basilar impression and invagination 
(Botelho and Ferreira, 2013; Kovero et al., 2006), as well as suggested to predispose the 
development of Chiari type I malformation (Fernandes et al., 2013). In platybasia, the 
clivus is oriented more horizontally than normally, which can be expected to co-exist with 
a more horizontally oriented and curved brainstem. This abnormal orientation is suggested 
to predispose to compression of the vertebral brainstem and tonsillar herniation. The 
longitudinal analysis in the present study indicated a recovery of platybasia during BP 
treatment in four patients with previous diagnosis, whereas in the previous study on 
patients predominantly naïve to BPs, platybasia persisted in all five patients originally 
diagnosed with it (Arponen et al., 2012), indicating potential recovering effect of BP 






older OI patients (Kovero et al., 2006), indicating potential naturally occurring recovery of 
platybasia. 
 
Overall, the preventing effect of BP treatment on the development of cranial base 
pathology remains unclear, and further studies with larger patient cohorts and longer 
follow-up time are required. 
6.2.2 The pattern of femoral fractures 
In the last few years, atypical femoral fractures (AFFs) have been a hot topic in the 
treatment of osteoporotic adults. A meta-analysis of several large population-based studies 
suggests an increased risk of AFF in adult patient with osteoporosis treated with BPs 
(Gedmintas et al., 2013). It should be noted, however, that the authors also state that the 
increased incidence of AFFs is likely to be outweighed by the overall reduction in the 
fracture risk associated with BPs. The same concern has recently received increasing 
attention in the treatment of children with OI, especially after Nicolaou and colleagues 
published their study, showing a remarkable shift towards subtrochanteric localization of 
femoral fractures associated to prolonged use of BPs (Nicolaou et al., 2012). 
 
AFFs are femoral fractures characterized by location in the shaft, a substantially transverse 
and minimally comminuted configuration, and flaring of the lateral cortex at the fracture 
site, which is detectable already before the fracture. According to the definition, AFF 
should also occur as a consequence of minimal or no trauma (Shane et al., 2014). Many of 
these features are, however, also typical of fractures occurring in children with OI, even 
without exposure to BPs. In the present study, up to 76% of femoral fractures were located 
in the femoral shaft, and 67% represented a transverse configuration. Therefore, caution 
should be exercised before defining a fracture as “atypical” in OI. The pathogenesis 
underlying the brittleness of bone in children with OI differs markedly from the one in 
postmenopausal osteoporosis. In addition to impaired collagen type I protein, the bone 
matrix is in fact hypermineralized in OI in contrast to hypomineralization, characteristic of 
postmenopausal osteoporosis (Traub et al., 1994). In addition to remodeling, the growing 






BPs to increase bone mass in children with OI is thought to be mainly due to their 
inhibitive effect on osteoclasts in modeling, leading to increased cortical thickness (Rauch 
et al., 2002) and reduced cortical porosity (Shapiro et al., 2003).  
 
In the present study, no difference in the characteristics of femoral fractures was found in 
terms of location and configuration related to BP treatment. Instead, the severity of the 
disease appeared to affect the pattern of fracture, location in the distal femur and 
transverse configuration being more common among the fractures occurred to patients 
with moderate to severe OI. Low bone mass and impaired material property of bone to 
resist bending forces in OI serve as a good explanation for the transverse configuration. 
The transverse configuration has, indeed, been found to be a frequent feature in long-bone 
fractures in OI, compared with healthy children (Dent and Paterson, 1991). The reason 
underlying the higher propensity to suffer distal femoral fracture is less clear. A previous 
finding that distal fractures also occur more frequently in children with disuse-associated 
osteoporosis (Lee and Lyne, 1990) suggests that disuse could be a contributor to the 
fracture risk, especially in more severe OI. 
 
Previous reports concerning the effects of BP exposure on the bone material properties are 
contradictory. Some studies with murine models have suggested that BPs in fact decrease 
in the material strength of bone, leading to even more brittle bones (Kashii et al., 2008; 
Uveges et al., 2009). These findings were made after 12-week treatment, corresponding to 
a treatment from toddler to young adulthood. Human studies have, however, suggested 
that up to 5 years of treatment with pamidronate does not compromise these properties in 
children with OI (Rauch et al., 2006; Weber et al., 2006). The difference in the treatment 
length seems to be a logical explanation for the contradiction of the results in these 
studies. The treatment length was, in addition to the smaller BP doses, a major difference 
between the present study and the study by Nicolaou and colleagues as well (Nicolaou et 
al., 2012). The average length of BP treatment preceding fractures was 6.5 years without 
standard “drug holidays”, whereas in the present study, the total duration was on average 
4.1 years divided into 1-3 years of treatment periods. Shorter treatments and use of 
standard “drug holidays” may have had a protective impact on bone against the adynamic 






6.2.3 The dental development 
The development and eruption of teeth requires resorption of the surrounding alveolar 
bone, and in case of permanent dentition other than molars, resorption of the roots of the 
primary teeth.  As anti-resorptive agents, BPs have been speculated to compromise this 
process, delaying tooth eruption. The phenomenon has been demonstrated in murine 
models (Bradaschia-Correa et al., 2007; Grier and Wise, 1998; Hiraga et al., 2010). There 
is, however, great difference between rodent and human dentitions. Rodents have for 
example only one dentition, and their incisors are in a state of continuous eruption. The 
molecular mechanisms of these continuously erupting incisors and teeth of limited 
eruption have been found to differ markedly (Wise and King, 2008). Hence, the findings 
made in murine models cannot be directly applied to humans. 
 
In humans, the evidence of delayed tooth eruption associated with BP exposure is scarce. 
Only one study considering the effect of BP treatment on tooth eruption has been 
published, by Kamoun-Goldrat and colleagues (Kamoun-Goldrat et al., 2008). In their 
study, they observed a reduced number of clinically erupted teeth in BP-treated children 
with OI compared with matched healthy controls. In the present study, a delaying effect 
was found as well, which did not, however, cause abnormal eruption of permanent 
dentition since the dental development was advanced in OI patients naïve to BPs. One 
factor contributing to the contradictory findings may be the lack of radiographic data in 
the study by Kamoun-Goldrat and colleagues, which may have led to overestimation of 
the impact of BPs since the number of emerged permanent teeth was not corrected for 
congenitally missing and impacted teeth. The prevalence of hypodontia is approximately 
20% in OI (Lukinmaa et al., 1987; Malmgren et al., 2017). The present study showed BPs 
to have a delaying effect on the resorption of the primary tooth roots as well. Since rodents 
have only primary dentition, it has not been possible to study this crucial part of eruption 
of most permanent teeth with murine models, and the finding is completely new, although 
not unexpected. 
 
The finding that dental development is advanced in terms of dental age and eruption of the 
permanent teeth in OI, is new. Previously, there have been very few studies concerning 






variation in the timing of dental development among 27 children with moderate to severe 
OI – in 5 of them, the dental age was advanced and in 4 delayed by more than 12 months 
(O'Connell and Marini, 1999). However, this seemed to be of little clinical consequence. 
Malmgren and Norgren reported that 1 out of 68 children with OI represented delayed 
tooth eruption, and the only one deviation concerned eruption of primary teeth (Malmgren 
and Norgren, 2002). At tissue level, the finding of accelerated dental development in OI 
appears to be logical since the acceleration of osteoclastic and osteoblastic activity is 
characteristic of OI (Rauch et al., 2000). 
 
Overall, according to the findings of the present study, BP treatment by delaying seemed 
to normalize the timing of the development of permanent dentition inherently advanced in 
OI. Yet, it is worth noting that the delaying effect of BPs may be detrimental in children 
with other medical indications to BP treatment. Future studies are required to show if such 
an effect really exists and is of clinical significance. 
6.3 Limitations of the study material 
 
Besides the fact that the present study was mainly retrospective, several other limitations 
were identified during this study as well, primarily related to the size and heterogeneity of 
the study cohorts due to the rarity of OI. Regarding the long-term effects of BP treatment, 
the patient population comprised children treated with three different BPs, zoledronic acid, 
pamidronate, and risedronate, and in some patients two different BPs were even used in 
their treatment at different time points. Therefore, no statistical comparison between 
different BPs was possible, and coefficients were used when evaluating the cumulative 
dose response. Since BPs have established their role in the treatment of children with OI, 
patients naïve to BPs, especially with moderate to severe OI, are scarce. Historical data 
was therefore used in the evaluation of the impact of BP treatment. This can potentially 
introduce some bias to the results due to differences in the clinical management other than 
medical treatment. In the longitudinal analysis in Study II, and in Study IV, historical 
control groups with OI were used. In Study III, the control group comprised the fractures 






group did not enable a proper age- and OI type-matching. The impact of age was 
minimized using reference values when available, and using age as covariate only with the 
resorption of the roots of the primary teeth. In Study II, age-matching was not required 
since the control group was used only in the longitudinal analysis. The study I did not 
include a control group at all, and it must be recognized that inclusion of a placebo or 
pamidronate group would have strengthened the data analyses. In Study III, the study 
material comprised fractures, which were divided into three groups according to status of 
BP treatment at the time of the trauma. Multiple fractures occurred in same patients were 
included, which may cause some bias. However, the use of possibly interrelated fractures 
should overestimate the impact of BP treatment and hence this does not challenge the 
results. As previously mentioned, the patient population can be estimated to comprise 
approximately 90% of the children with OI born during the study period. Therefore, to 
acquire larger and more homogenous patient populations, international co-operation is 
required in the future. 
 
The data of the present study was collected during a time when “drug holiday” after 2-3 
years of BP treatment was a common clinical practice in Finland. Hence, it is worth noting 
that the results concerning long-term effects of BP treatment should be generalized only to 
BP treatments carried out in a similar protocol. Currently, several centers worldwide use 
BPs for much longer periods or apply maintenance treatment with low dose BPs instead of 
“drug holiday”. In these situations, the adynamic bone effect of BP treatment may be more 
prominent. 
6.4 Future perspective 
Although three decades have passed since the first reports of the use of BP therapy in 
children with OI, and hundreds of studies concerning its efficacy and safety have been 
published ever since, much still remains  unclear. This is especially true with the optimal 
treatment protocol. Whether treatment should be paused at 2-3 years, after the maximal 
benefits on bone mass and density have been obtained, and restarted individually 
according to need, or whether maintenance treatment with a lower dose of intravenous or 






nowadays been applied more and more frequently, also here in Finland, it would be 
interesting to compare these two treatment protocols concerning for instance potential 
fractures occurring in the junction of the treated and untreated bone, and manifestations of 
adynamic bone effects of BP treatment. Furthermore, since the knowledge of the impact of 
BP treatment on fracture healing is still scarce and considering the available data on 127 
femoral fractures, it seems logical also to evaluate the healing of these fractures and assess 







The purpose of this study was to evaluate benefits and long-term safety of BP therapy in 
the treatment of children with OI, and to assess the use of zoledronic acid instead of the 
most commonly used intravenous BP pamidronate in the treatment of children with mild 
OI. Based on the findings of the study, the following conclusions are presented: 
 
I Intravenous zoledronic acid can be regarded as effective and safe treatment in 
children with mild OI. 
 
II Cranial base pathology may develop despite BP treatment. Treatment started in 
infancy may, however, have a delaying effect on the development of cranial base 
anomalies, supporting an early initiation of the treatment. 
 
III No evidence of changing pattern in femoral fractures related to BP exposure was 
found in children with OI. Instead, the characteristics of these fractures seemed to 
reflect the severity of OI. 
 
IV BP treatment delays the development and eruption of permanent dentition in patients 
with OI. Since the development and eruption of permanent dentition is according to 
our findings inherently accelerated in children with OI, the overall delay due to BP 
exposure in therapeutical doses is likely to normalize the timing of permanent 
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